VANCOUVER, British Columbia, Aug. 16, 2022 (GLOBE NEWSWIRE) — Ottawa’s drug pricing modifications could lead to decrease prices, however can even probably scale back Canadians’ entry to life-saving prescribed drugs and doubtlessly discourage funding in Canada’s pharmaceutical sector, finds a brand new research launched as we speak by the Fraser Institute, an impartial, non-partisan Canadian public coverage think-tank.
“The core issue is that Ottawa’s changes to the Patented Medicines Regulations are intended to reduce prices, but will also likely result in delayed – or worse, limited – access to new life-saving medicines,” mentioned Kristina Acri, Chair of the Economics and Business Department at Colorado College, senior fellow on the Fraser Institute and writer of An Evaluation of the Proposed PMPRB Amendments.
The Patented Medicines Prices Review Board’s (PMPRB) not too long ago introduced amendments to the Patented Medicines Regulations.
The amendments notably change the group of nations used for comparability to find out drug costs in Canada. Specifically, Switzerland and the United States have been eliminated in favour of a set of nations that usually have decrease costs, but in addition entry to fewer new and progressive medication.
These modifications could have important penalties for Canadians as a result of the potential decrease costs will discourage pharmaceutical firms from launching new merchandise in Canada. Moreover, Ottawa’s modifications designed to cut back drug costs can even scale back the monetary incentives to develop and manufacture new medicines, remedies, and cures in Canada.
Crucially, COVID-19 vaccines had been successfully exempt from common PMPRB pricing oversight, suggesting that the federal authorities is conscious of the discouraging impact such restrictions have on innovation within the pharmaceutical business.
“Affordability is important but so, too, is making sure Canadians have access to the best medicines in the world,” Acri mentioned.
“Ottawa’s proposed changes to drive down drug prices will have an impact on peoples’ access to new life-saving medicines, and Canadians should be aware of the trade-off the government is making.”
MEDIA CONTACT:
Kristina Acri, Senior Fellow
Fraser Institute
To prepare media interviews or for extra info, please contact:
Drue MacPherson, 604-688-0221 ext. 721, [email protected]
Follow the Fraser Institute on Twitter and Facebook
The Fraser Institute is an impartial Canadian public coverage analysis and academic group with places of work in Vancouver, Calgary, Toronto, and Montreal and ties to a world community of think-tanks in 87 international locations. Its mission is to enhance the standard of life for Canadians, their households and future generations by learning, measuring and broadly speaking the results of presidency insurance policies, entrepreneurship and selection on their well-being. To shield the Institute’s independence, it doesn’t settle for grants from governments or contracts for analysis. Visit www.fraserinstitute.org
